• Moderna announced published results in JAMA Network Open comparing its mNEXSPIKE COVID-19 vaccine with Comirnaty.
• The real-world study included 294,499 matched US veterans aged 65 and older during the 2025-2026 respiratory virus season.
• mNEXSPIKE was associated with fewer COVID-19 hospitalizations and medically attended cases than Comirnaty.
• An exploratory analysis also linked mNEXSPIKE to fewer hospitalizations involving major adverse cardiovascular events.
• The observational findings do not establish causality; the predominantly older, male population may limit applicability to broader populations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202611111110ACCESSWRNAPR_____1249376) on November 11, 2026, and is solely responsible for the information contained therein.